383 related articles for article (PubMed ID: 26460956)
61. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.
Farolfi A; Melegari E; Aquilina M; Scarpi E; Ibrahim T; Maltoni R; Sarti S; Cecconetto L; Pietri E; Ferrario C; Fedeli A; Faedi M; Nanni O; Frassineti GL; Amadori D; Rocca A
Heart; 2013 May; 99(9):634-9. PubMed ID: 23349345
[TBL] [Abstract][Full Text] [Related]
62. Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy.
Huang P; Dai S; Ye Z; Liu Y; Chen Z; Zheng Y; Shao X; Lei L; Wang X
Oncotarget; 2017 Jan; 8(2):2069-2075. PubMed ID: 27906683
[TBL] [Abstract][Full Text] [Related]
63. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study.
Wadhwa D; Fallah-Rad N; Grenier D; Krahn M; Fang T; Ahmadie R; Walker JR; Lister D; Arora RC; Barac I; Morris A; Jassal DS
Breast Cancer Res Treat; 2009 Sep; 117(2):357-64. PubMed ID: 19082707
[TBL] [Abstract][Full Text] [Related]
64. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
[TBL] [Abstract][Full Text] [Related]
65. Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients.
Marinko T; Stojanov Konda JT; Dolžan V; Goričar K
Dis Markers; 2020; 2020():6645588. PubMed ID: 33425072
[TBL] [Abstract][Full Text] [Related]
66. [Cardiac safety of trastuzumab in adjuvant: a review across 53 observations].
Tanz R; Mahfoud T; Bazine A; Khmamouch R; Bensouda Y; Ismaili N; Benjaafar N; El Gueddari BK; Ichou M; Errihani H
J Gynecol Obstet Biol Reprod (Paris); 2011 Apr; 40(2):144-8. PubMed ID: 21227599
[TBL] [Abstract][Full Text] [Related]
67. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JG; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ
J Clin Oncol; 2007 Sep; 25(25):3859-65. PubMed ID: 17646669
[TBL] [Abstract][Full Text] [Related]
68. Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function?
Lu CY; Srasuebkul P; Drew AK; Chen K; Ward RL; Pearson SA
Breast; 2013 Aug; 22(4):482-7. PubMed ID: 23664254
[TBL] [Abstract][Full Text] [Related]
69. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.
Kaboré EG; Guenancia C; Vaz-Luis I; Di Meglio A; Pistilli B; Coutant C; Cottu P; Lesur A; Petit T; Dalenc F; Rouanet P; Arnaud A; Arsene O; Ibrahim M; Wassermann J; Boileau-Jolimoy G; Martin AL; Lemonnier J; André F; Arveux P
PLoS Med; 2019 Dec; 16(12):e1002989. PubMed ID: 31869400
[TBL] [Abstract][Full Text] [Related]
70. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
71. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG).
İçli F; Altundağ K; Akbulut H; Paydaş S; Başaran G; Saip P; Doğu GG; Eralp Y; Uslu R; Sevinç A; Onur H; Mandel NM; Sezgin C; Altınbaş M; Güler N; Işıkdoğan A; Gökmen E; Uygun K; Üstüner Z; Yaren A; Demirkan B; Coşkun U; Ata A; Özkan M; Arican A
Breast Cancer; 2015 Sep; 22(5):480-5. PubMed ID: 24338610
[TBL] [Abstract][Full Text] [Related]
72. [Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy].
Kirova YM; Caussa L; Granger B; Savignoni A; Dendale R; Campana F; Tournat H; Pierga JY; Fourquet A; Bollet MA
Cancer Radiother; 2009 Jul; 13(4):276-80. PubMed ID: 19447661
[TBL] [Abstract][Full Text] [Related]
73. Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.
Leung HW; Chan AL
Expert Opin Drug Saf; 2015; 14(11):1661-71. PubMed ID: 26461271
[TBL] [Abstract][Full Text] [Related]
74. Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series.
Meattini I; Cecchini S; Muntoni C; Scotti V; De Luca Cardillo C; Mangoni M; Bonomo P; Nori J; Casella D; Simoncini R; Orzalesi L; Bianchi S; Livi L
Med Oncol; 2014 Apr; 31(4):891. PubMed ID: 24535610
[TBL] [Abstract][Full Text] [Related]
75. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer.
Russo G; Cioffi G; Gori S; Tuccia F; Boccardi L; Khoury G; Lestuzzi C; Maurea N; Oliva S; Faggiano P; Tarantini L;
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):141-6. PubMed ID: 24534802
[TBL] [Abstract][Full Text] [Related]
76. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
77. The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis.
Wu YY; Huang TC; Tsai TN; Chen JH; Dai MS; Chang PY; Ho CL; Ye RH; Chung TR; Chen YC; Chao TY
PLoS One; 2016; 11(3):e0151112. PubMed ID: 26953588
[TBL] [Abstract][Full Text] [Related]
78. Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study.
Sawaki M; Mukai H; Tokudome N; Nakayama T; Taira N; Mizuno T; Yamamoto Y; Horio A; Watanabe T; Uemura Y; Ohashi Y
Breast Cancer; 2012 Jul; 19(3):253-8. PubMed ID: 21526424
[TBL] [Abstract][Full Text] [Related]
79. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
80. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
